

CancerPACTtm



Cancer Patients' Alliance for Clinical Trials

Los Angeles Area Adult Cancer Clinical Trials Major Cancer Centers Winter 2010

Solid Tumors

1. Breast	2
2. Central Nervous System	6
3. Gastrointestinal	7
4. Gynecologic	12
5. Head and Neck	15
6. Lung	15
7. Melanoma	19
8. Prostate	20
9. Urologic (other)	22
10. Sarcoma	23

Hematologic Cancers

1. Leukemia	24
2. Lymphoma	27
3. Myeloma	29

Phase I Studies	31
------------------------------	----

Other	32
--------------------	----

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
City of Hope (COH) 877-482-4673
Loma Linda University Medical Center (LLU) 800-782-2623
UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
USC Clinical Trials Unit (CTU) 323-442-9960
USC Norris Cancer Center (USC) 323-865-0451

CancerPACT is an initiative of the Lorenzen Cancer Foundation

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Solid Tumors

1. Breast Cancer

1. **04-03-024 Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (Suppression of Ovarian Function Trial [SOFT]) (UCLA)**
2. 05-06-022 Phase III Randomized Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or II Breast Cancer (NSABP B-39) (UCLA)
3. **08-05-023, 1B08-2 Phase III Multicenter Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab [NSABP B-44-I / BO20906] (UCLA, USC)**
4. 08-10-035 Phase II Multicenter Open-Label Randomized Trial of Presurgical Treatment with Single-Agent Lapatinib (Ty) or Trastuzumab (H) or the combination of Trastuzumab and Lapatinib (H+ Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2/Neu-Amplified Breast Cancer (UCI)
5. **08-11-060 Phase III Multicenter Multinational Randomized Double-Blind Study of IMC-1121 B Plus Docetaxel vs. Placebo Plus Docetaxel in Previously Untreated Patients with Her2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer (UCLA)**
6. 1305, 1B-07-3 Phase III Randomized Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CTU, USC)
7. **09131 Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy (COH)**
8. CTSU/ACOSOGZ1031 Phase III Randomized Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Post-Menopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer (USC)
9. **CTSU/IBCSG2402 Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-Menopausal Women with Endocrine Responsive Breast Cancer (USC)**
10. ECOG PACCT-1/HS 2006-5364 Phase III Study of Adjuvant Combination Chemo + Hormonal Therapy vs. Adjuvant Hormonal Therapy Alone in Women with Previously Resected Axillary Node-Negative Breast Cancer with Various Levels of Risk for Recurrence (TAILORx Trial) (UCI)

Contact Organizations:

[Cedars-Sinai \(CS\) 800-233-2771](#)
[City of Hope \(COH\) 877-482-4673](#)
[Loma Linda University Medical Center \(LLU\) 800-782-2623](#)
[UC Irvine Chao Family Comprehensive Cancer Center \(UCI\) 877-827-8839](#)
[UCLA-Jonsson Comprehensive Cancer Center \(UCLA\) 888-798-0719](#)
[USC Clinical Trials Unit \(CTU\) 323-442-9960](#)
[USC Norris Cancer Center \(USC\) 323-865-0451](#)

Call (toll free) 1-888-729-0244
www.CancerPACT.org

11. **NSABP-B40 Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens (LLU)**
12. RTOG 0413 Phase III Randomized Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (UCLA)
13. **SWOG-N063D ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study) Phase III Randomized Multi-Centre Open-Label Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study (LLU)**
14. SWOG-S0221 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer (USC)
15. **SWOG-S0230 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer (USC)**
16. SWOG-S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer (USC)
17. **SWOG-S0500 Phase III Randomized Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy for Metastatic Breast Cancer Patients who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment (LLU, USC)**
18. SWOG-S0715 Phase III Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane-Induced Neuropathy (USC)
19. **1B-09-1 Phase II Multi-Center Randomized Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer (USC)**
20. 1B-09-4 Phase II Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic Breast Cancer Whose Disease has Failed Prior Taxane-Based Treatment (USC)
21. **05042 Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Mephalan and Carboplatin, Thiotepa, and Cyclophosphamide (STAMP V)+/-Trastuzumab followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer (COH)**
22. UCI 03-16 / HS 2004-3681 Phase II Chemoprevention Trial of Anastrozole in the DCIS and Early Invasive Breast Cancer in Postmenopausal Women (UCI)
23. **UCI 07-61 / HS 2007-6084 Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (UCI)**
24. 08-08-055 Phase II Randomized Multicenter Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in Patients with Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease (UCLA)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

25. CRAD 001J2101 Phase IB/II Study Investigating the Combination of RAD001 with Trastuzumab and Paclitaxel in Patients with HER2-Positive Metastatic Breast Cancer (LLU)
26. **08-05-091 Phase I/II Open-Label Randomized Study of the Safety, Efficacy and Pharmacokinetics of Letrozole Single Agent Versus Letrozole Plus PD-0332991 (Oral CDK 4/6 Inhibitor) for the First-Line Treatment of ER Positive, Her-2 Negative Metastatic Breast Cancer in Postmenopausal Women [Pfizer AA5481003] (UCLA)**
27. 1312, 1B-09-7 Phase I/II Open-Label Study of Neratinib (HKI-272) in Combination with Capecitabine in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or Locally Advanced Breast Cancer (3144A1-2206WW) (CTU, USC)
28. **08008 Phase I/II Study of HKI-272 in Combination with Vinorelbine in Subjects with Solid Tumors and Metastatic Breast Cancer (COH)**
29. 08103 Phase I/II Vinorelbine and Sorafenib as Salvage Therapy in Metastatic Breast Cancer (COH)
30. **Phase I/II Study of R1507 in Combination with Letrozole for Postmenopausal Women With ER+, HER2- Advanced Breast Cancer (CS)**
31. 07-06-027 Phase I Dose Escalation Multi-Center Open-Label Study of AU922 Administered IV on a Once-Weekly Schedule in Adult Patients with Advanced Solid Malignancies Including Phase II Expansion Arms in Patients with Either Her2 Positive or ER Positive Locally Advanced or Metastatic Breast Cancer (UCLA)
32. **0S-08-2 Prospective Multi-Center Study of the Role of Positron Emission Mammography in Pre-Surgical Planning for Breast Cancer (USC)**
33. 0S-08-5 Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project (USC)
34. **0S-08-8 Assessment of the Clinical Value of Supersonic Shear Wave Elastography in the Ultrasonic Evaluation of Breast Lesions (USC)**
35. 0S-08-16 Family Communication of BRCA Genetic Test Results among Latina Women (USC)
36. **1B-04-4 An International Randomized Controlled Trial to Compare Targeted Intra-Operative Radiotherapy with Conventional Post-Operative Radiotherapy after Conservative Breast Surgery for Women with Early Stage Breast Cancer (USC)**
37. 1B-06-9 Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT (USC)
38. **1B-06-10 EphB4 Expression in Human Breast Cancer (USC)**
39. 1B-08-1 Pilot Study of Green Tea Supplement in Women with Ductal Carcinoma in Situ (USC)
40. **00080 Optical Biosensor for the Early Detection of Breast Cancer (COH)**
41. 04125 Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up (COH)
42. **06102 Reducing the Burden of Breast Cancer Among African American and Latina Survivors (COH)**
43. 06136 Support for Hispanic Breast Cancer Patients and Caregivers (COH)
44. **06138 Barriers and Outcomes of Delays in Breast Cancer Treatment (COH)**
45. 06139, NSABP B-42, HS 2007-5573, 06-10-083 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

- an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (COH, LLU, UCI, UCLA, USC)
46. **07006 The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients with Breast Cancer (COH)**
 47. 07100 Long Term Follow-Up After Breast Cancer (COH)
 48. **07120 Pro Inflammatory Cytokines and Neurobehavioral Symptoms in Women with Breast Cancer (COH)**
 49. 07213 Translational Breast Cancer Prevention Trial of Mushroom Powder in Postmenopausal Breast Cancer Survivors (COH)
 50. **08061 Mindful Movement Program for Breast Cancer Survivors (COH)**
 51. 08063 Intermittent Exemestane Therapy for Metastatic Breast Cancer (COH)
 52. **08092 Patient Navigation in Breast Cancer Care; Addressing Barriers to Treatment Initiation, Completion, and Follow Up (COH)**
 53. 08128 Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients with Locally Advanced or Metastatic Stage IV Breast Cancer (COH)
 54. **08194 Communication in Asian American Families with Breast Cancer Survivors (COH)**
 55. 08203 Women at Increased Breast Cancer Risk: the Decision for Prophylactic Mastectomy (COH)
 56. **09032 Inflammatory Breast Cancer (BC) Registry (COH)**
 57. 97105 Evaluation of Breast Cancer Patterns and Outcomes of Care (COH)
 58. **UCI 02-10 / HS 2002-2306 Monitoring the Response of Chemotherapy on Breast Cancer Tumors by Photon Migration Spectroscopy (UCI)**
 59. UCI 00-09 / HS 2000-1141 Angiogenesis in Early Breast Cancer for Prognosis Prediction (UCI)
 60. **UCI 06-47 / HS 2006-5283 Breast Cancer Stem/Progenitor Cell Repository Protocol (UCI)**
 61. UCI 08-19 / HS 2008-6528, 1B-08-6 MarginProbe, A Device for Intraoperative Assessment of Margin Status in Breast Conservation Surgery (CS, UCI, USC)
 62. **UCI 08-38 HS 2008-6549 Study of Chemotherapy Side Effects in Breast Cancer Patients: Non-Invasive Optical Measurements of the Brain (UCI)**
 63. UCI 95-29 / HS 1995-563 Measurement of Breast Optical Properties (UCI)
 64. **Breast Cancer Outcomes Comparing Neratinib vs. Placebo (CS)**
 65. Collection of Blood and Tissue for the Early Detection of Breast Cancer (CS)
 66. **GeneSearch Breast Cancer Lymph Node Assay (CS)**
 67. Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (CS)
 68. **Randomized Trial to Study the Safety and Effectiveness of Pertuzumab + Trastuzumab + Docetaxel vs. Trastuzumab + Docetaxel in Patients with Untreated, HER2-Positive, Metastatic Breast Cancer (CS)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

2. Central Nervous System Tumors

1. **08096, RTOG-0614 Phase III Randomized Double- Blind Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy (COH, USC)**
2. 09066 Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma (COH)
3. **1275 Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (CTU)**
4. 07107 Phase IIA Study of ADV-TK + Valacyclovir Gene Therapy in Combination with Standard Radiation Therapy for Malignant Gliomas (COH)
5. **05-10-007 Phase II Clinical Trial Evaluating DCVax-Brain Autologous Dendritic Cells Pulsed with Tumor Lysate Antigens for the Treatment of Glioblastoma (UCLA)**
6. 07-03-050 Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas (UCLA)
7. **07094 RTOG #0627 Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma Multiforme (COH)**
8. 08051 Phase II Exploratory Study Evaluating the Efficacy and Safety of Fibrin Sealant, Vapor Heated, Solvent/Detergent Treated (FS VH S/D) 500 S-APR for the Sealing of Dura Defect Sutures in Posterior Fossa Surgery (COH)
9. **06-01-052 Phase I/II Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients (UCLA)**
10. 06-04-030 Phase I/II Studies of Bay 43-9006 (Sorafenib) in Combination with OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temozolomide) in Patients with Recurrent Glioblastoma Multiforme or Gliosarcoma (UCLA)
11. **06-04-104 Phase I/II Dual-Center Open-Label Trial of the Safety and Efficacy of Tarceva (Erlotinib Hydrochloride) Plus Sirolimus in Patients with Recurrent Malignant Glioma not on P450-Inducing Anti-Epileptics (UCLA)**
12. 03-04-053 Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas (UCLA)
13. **05-12-061 Phase I Study of Vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in Combination with Temozolomide in Patients with Malignant Gliomas (NABTC04-03) (UCLA)**
14. 08-01-061 Phase 1 Dose-Escalation Study of XL765 in Combination with Temozolomide in Subjects with Malignant Gliomas (UCLA)
15. **08-09-042 Phase I Trial of Aflibercept (VEGF Trap) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma (UCLA)**
16. 6CNS-07-1 Establishment of USC CNS and Spine Tumor Bank (USC)
17. **07-01-003 Dose Intensive Chemotherapy For Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens. Followed by Consolidation with Myeloablative Chemotherapy (Thiotepa and Carboplatin, with or without Etoposide) and Autologous Stem Cell Rescue (UCLA)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

18. 07064 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temozolomide in Patients with Primary or Metastatic Brain Tumors (COH)
19. **07250 A Behavioral Intervention Trial for Parents of Childhood Cancer Survivors with Neurobehavioral Late Effects (COH)**
20. 08070 BIBW 2992 With or Without Daily Temozolomide in the Treatment of Patients with Recurrent Malignant Glioma (COH)
21. **09062 Elucidating Glioma Cellular Heterogeneity by Stem Cell Lineage Mapping for Therapeutic Advantage (COH)**
22. Azixa (MPC-6827) For Patients with Recurrent Glioblastoma Multiforme (CS)
23. **Bradmer Neuradiab Study for Glioblastoma (CS)**
24. Cilengitide for Patients with Newly Diagnosed GBM and Methylated MGMT Gene Promoter (CS)
25. **Dendritic Cell Vaccine with Imiquimod for Patients with Malignant Glioma (CS)**
26. Gliadel and Dendritic Cell Vaccine for Patients with Malignant Glioma (CS)
27. **Immunotherapy for Glioblastoma and Brain Stem Glioma (CS)**
28. Laser Fluorescence for Brain Tumors (CS)
29. **Metabolic Cerebral Imaging in Incipient Dementia: Early and Long-Term Value of Imaging Brain Metabolism (CS)**
30. Randomized, Parallel Group, Multi Centre Study in Recurrent Glioblastoma to Compare the Efficacy of AZD2171 (RECENTIN) and the Combination of AZD2171 with Lomustine to the Efficacy of Lomustine Alone (CS)
31. **Research Study to Test the Safety and Effectiveness of Oral Memantine vs. Placebo in the Prevention of Cognitive Dysfunction / Disorders in Patients who have Received Radiotherapy of the Whole-Brain (CS)**
32. Screening Protocol to Determine Potential Eligibility of Patients for IRB-Approved Vaccine Trials (CS)
33. **The Brain and CNS Tissue Registry: Immunologic, Vascular and Genetic Assessment, Storage and Distribution of Brain and CNS Tumors, Lesions, Nonneural Tissue, Vascular Tissue, Epileptic Tissue, Tissue from Brain Trauma, Neuro Vascular and CNS Disease Tissue (CS)**

3. Gastrointestinal Cancers

A. Colorectal Cancer

1. **04080 CTSU/NCCTGN0147, SWOG-N0147 Phase III Randomized Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or w/o Cetuximab (C225) After Curative Resection for Patients with Stage III Colon Cancer (COH, LLU)**
2. 06152, CALGB/SWOG C80405 Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (COH, USC)
3. **SWOG-E5202 Phase III Randomized Study comparing 5-FU, Leucovorin and Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively and Prognostic Value of Molecular Markers (LLU)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

4. SWOG-S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX (LLU, UCI)
5. **08-03-081 Phase IIB Randomized Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) vs. Bevacizumab Plus FOLFOX as First-Line Treatment in Patients with Metastatic Colorectal Cancer (UCLA)**
6. UCI 07-47 / HS 2007-5892 Phase IIA Clinical Biomarker Trial of Aspirin and Arginine Restriction in Familial Colon Cancer Patients (UCI)
7. **3C-07-4 Phase II Double-Blind Randomized Placebo-Controlled Study of Enzastaurin with 5-FU/LV plus Bevacizumab as Maintenance Regimen Following First-Line Therapy for Metastatic Colorectal Cancer (USC)**
8. 3C-09-1 Phase II Open-Label Multi-Center Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients with Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status (USC)
9. **3C-09-2 Phase II Multi-Center Open-Label Randomized Study to Evaluate the Efficacy and Safety of NKTR-102 (PEG-Irinotecan) vs. Irinotecan in Patients with Second-Line, Irinotecan-Naïve, KRAS-Mutant, Colorectal Cancer with Metastatic or Locally Advanced Disease (USC)**
10. 07-08-034 Phase II Multi-Center Open-Label Randomized Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects with Metastatic Colorectal Cancer SPIRITT (“Second-Line Panitumumab-Irinotecan Treatment Trial”) (CS, UCLA)
11. **1193 Phase II Single Arm Study of the Efficacy, Safety and Biomarkers of Activity of E7820 plus Cetuximab in Patients with Colorectal Cancer Preceded by a Run-In Study to Determine Safety of the Combination in Advanced Solid Tumors (3C-06-2) (CTU)**
12. SWOG-S0713 Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Radiation in Pre-Operative Therapy of Rectal Cancer (USC)
13. **ZOO Z6041 / HS 2006-5355 Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer (UCI)**
14. UCI 08-27 / HS 2008-6605 Phase IB/II Study of AMG 655 in Combination with Modified FOLFOX6 & Bevacizumab for the First-Line Treatment of Subjects with Metastatic Colorectal Cancer (UCI)
15. **3C-03-19 Phase I/II Study of Celebrex and EPO906 in Patients with Metastatic Colorectal Cancer (CEPO906AUS10) (USC)**
16. 3C-07-5 Phase I/II Blinded Randomized Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in K-Ras Wild Type Subjects with Metastatic Colorectal Cancer (USC)
17. **1267 Phase I/II Blinded Randomized Study of Brivanib Alaninate vs. Placebo in Combination with Erbitux and Irinotecan in Subjects with Metastatic Colorectal Cancer (3C-07-5) (CTU)**
18. 09-04-007 Phase IB Study of the Safety and Pharmacokinetics of Apo2L/TRAIL Administered in Combination with the Folfox Regimen and Bevacizumab in Patients with Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer (UCLA)
19. **08005 Phase I Study of Ursodeoxycholic Acid in Combination with 5-Fluorouracil, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Metastatic Colorectal Cancer (COH)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

20. UCI-07-58 Phase I Biomarker Study of Dietary Grape-Derived Low Dose Resveratrol for Colon Cancer Prevention (UCI)
21. **04122 Phase I Trial of Radioimmunotherapy (Y90 cT8.66), Gemcitabine and Hepatic Arterial Infusion of Fudr for Metastatic Colorectal Carcinoma to the Liver (COH)**
22. 04197 NSABP R-04 Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum (COH)
23. 05130 Evaluation of Colon/Rectal Cancer Patterns and Outcomes of Care (COH)
24. **06183 The Role of Gene Expression in Predicting Response to Chemoradiation in Advanced Rectal Cancers (COH)**
25. 07169 Understanding Comorbidity in Patients with Colon Cancer (COH)
26. **07182, UCI 05-25 / HS 2005-4376 Timing of Rectal Cancer Response to Chemoradiation (COH, UCI)**
27. NSABP-R-04 Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carinoma of the Rectum (LLU, USC)
28. **UCI 04-05 / HS 2004-3560 Investigation into the Molecular Causes of Colon and Rectal Cancers (UCI)**

B. Esophageal Cancer

1. **07-12-010 Phase II Study of Erlotinib and modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia (UCLA)**
2. 09-07-061 Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach (UCLA)
3. **06249 Phase II Random Assignment Study of Modified Docetaxel, Cisplatin, and Fluorouacil (mDCF) versus Parent DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (COH)**
4. 1321 3G-09-1 Phase IB Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas (CTU)
5. **Collection of Data for the Society of Thoracic Surgeons (STS) Database for Patients that Will Undergo a Chest or Lung Procedure (CS)**

C. Gastric Cancer

1. **08206 Phase III Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Nilotinib vs. Imatinib in Adult Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) (COH)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

2. 3G-03-4 Phase II Study of Oxaliplatin, Xeloda, and Cetuximab as First-Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer (USC)
3. **3G-03-5 Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma (USC)**
4. 3G-07-1 Phase II Randomized Study of Patients with Locally Advanced Gastric or Gastro-Esophageal Adenocarcinoma Treated with Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine Followed By Prolonged Administration of Capecitabine (USC)
5. **3S-07-1 Phase II Exploratory Trial to Determine the Association of Lapatinib-Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First-Line Gastric Cancer (USC)**
6. 09-07-061 Phase II Study of the mTOR inhibitor RAD001 in Previously Treated Patients with Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach (UCLA)
7. **GLAXO-LPT109747 Phase II Exploratory Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer (LLU)**
8. UCI 07-38 / HS 2008-6123 Phase II Exploratory Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes with Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer (UCI)
9. **0S-99-10 Blood Collection in Patients with GI Cancer (USC)**
10. 3G-07-3 Establishing Continuous Cell Lines and Xenografts from Adult Gastrointestinal Cancers and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies (USC)
11. **3G-07-4 Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers (USC)**

D. Pancreatic Cancer and Neuroendocrine Tumors

1. **SWOG-S0518 Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients (USC)**
2. **UCI 03-11 / HS 2003-2981, 02-07-023 Phase II/III Randomized Study of TNFerade Biologic with 5-Fu Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer (UCI, UCLA)**
3. UCI-06-30 Phase IIA Trial Testing Erlotinib as an Intervention Against Intraductal Pancreatic Mucinous Neoplasms (UCI)
4. **ACOSOG-Z5041, HS 2009-6775 Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma (LLU, UCI)**
5. UCI 08-09 / HS 2008-6322, 06-08-070 Phase II Double-Blind Placebo Controlled, Multi-Center Adjuvant Trial of Efficacy, Immunogenicity, & Safety of GI-4000; An Inactivated Recombinant

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Saccharmyces Cerevisiae Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen w/Placebo in Patients w/Post-Resection RO/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations (UCI, UCLA)

6. **UCI 08-13 / HS 2008-6492, 3P-08-1 Phase II Study of HyperAcute-Pancreatic Cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer (UCI, USC)**
7. 1291, 0S-08-12 Phase II Multicenter Two-Tier Study of IMC-A12 in Combination with Depot Octreotide in Patients with Metastatic, Well-or Moderately-Differentiated Carcinoid or Islet Cell Carcinoma (CTU, USC)
8. **08122, SWOG S0727 Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-724460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer (COH, USC)**
9. NOVARTIS-CSOM230C2303 Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients with Metastatic Carcinoid Tumors Whose Disease-Related Symptoms are Inadequately Controlled by Somatostatin Analogues (LLU)
10. **UCI 02-69 / HS 2003-2972 Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma (UCI)**
11. 06223 ADV-TK Therapy in Combination with Surgery and Chemoradiation for Pancreas Cancer (COH)
12. **08033 A Standardized Nursing Intervention Protocol for Pancreatic Cancer as a Chronic Illness (COH)**
13. UCI 08-70 / HS 2009-6733 Establishment of a Multidisciplinary Pancreatic Tumor Biorepository and Integrated Clinical Database (UCI)

E. Liver Cancer

1. **3L-09-2 Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMC-A12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma (USC)**
2. UCI 08-42 / HS 2008-6697 Phase III Multinational Randomized Open-Label Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (UCI)
3. **3L-08-2 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation (STORM) (USC)**
4. UCI 08-42 / HS 2008-6697 Phase III Multinational Randomized Open-Label Study of Sunitinib Malate versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (UCI)
5. **1285, 3L-08-1 Phase I Open-Label Multi-Center Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of GC33, a Recombinant Humanized Antibody to Glypican-3 Administered Weekly in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) (CTU, USC)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

6. 08243 Phase I Open Label/Phase II Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients with Advanced Hepatocellular Carcinoma (COH)
7. **3L-03-1 Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma (USC)**
8. UCI 08-64 / HS 2009-6782 Phase I/II Randomized Multi-center Open-label Trail of PR104 and Sorafenib in patients with advanced Hepatocellular Carcinoma, PR104-2002 (UCI)
9. **3L-09-1 GIDEON: Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (USC)**
10. 06057 A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere (Yttrium-90 Glass Microspheres): A HDE Treatment Use Protocol (COH)

4. Gynecologic Cancers

A. Ovarian / Peritoneal Cancer

1. **5GYN-07-1 Phase III Multi-Center Randomized Blinded Placebo-Controlled Trial of Carboplatin and Gemcitabine plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma (USC)**
2. 09016 Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Peritoneal Primary and Fallopian Tube Cancer (COH)
3. **09125 Phase III Randomized, Multicenter Open-Label Study of the Efficacy and Safety of Trastuzumab-MCC-DM1 VS. Capecitabine + Lapatinib in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy (COH)**
4. GOG-0212 Phase III Randomized Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND #70177) vs. No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy (UCI)
5. **GOG-0218 Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (Rhumab VEGF, NSC #704865, IND #7921) Followed by Placebo, vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian and Peritoneal Primary Cancer (UCI)**
6. UCI-09-18 Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (UCI)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

7. **Phase III Study Comparing Phenoxodiol with Carboplatin to Carboplatin Alone for Advanced, Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer (CS)**
8. 5GYN-06-3 Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft Tissue Sarcomas (USC)
9. **5O-08-2 Phase II Randomized Double-Blind Placebo-Controlled Multi-Center Study of Adding AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) to First-Line Chemotherapy in Patients with Optimally Debulked (<1 cm) Epithelial Ovarian (USC)**
10. 5O-08-3 Phase II Multi-Center Open Label Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) as Second-Line Therapy in Patients with Recurrent Platinum-Sensitive Ovarian Cancer (USC)
11. **5O-09-1 Phase II Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of NKTR-102 (PEG-Irinotecan) When Given on a Q14 Day or a Q21 Day Schedule in Patients with Metastatic or Unresectable Locally Advanced Platinum-Resistant Ovarian Cancer (USC)**
12. 08048 GOG-0215 Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on the Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery that Results in Removal of Both Ovaries (COH)
13. **09100 Phase II Trial of Temozolomide and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer (COH)**
14. GOG-0239 Phase II Trial of AZD6244 (NSC #741078, IND #77782) in Women with Recurrent Low Grade Serous Carcinoma of the Ovary (USC)
15. **UCI-08-43 Phase II Multicenter Randomized Double-Blind Placebo-Controlled Trial Evaluating The Efficacy and Safety of GDC-0449 as Maintenance Therapy in Patients with Ovarian Cancer in a Second or Third Complete Remission (UCI)**
16. **GOG-0205 Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva (UCI)**
17. 09128 Phase IB Parallel Arm Multicenter Open-Label Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination with Two Different Chemotherapy Regimens in Women with Platinum Resistant or Platinum Sensitive Ovarian Cancer (CS)
18. **08059 Phase I Trial of Intraperitoneal nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity (COH)**
19. GOG-9916 Phase I Trial of Intravenous Paclitaxel Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel or Intravenous Docetaxel, Intraperitoneal Carboplatin and Intraperitoneal Paclitaxel in Patients with Previously Untreated Epithelial Ovarian Carcinoma, Fallopian Tube or Primary Peritoneal Carcinoma (UCI)
20. **GOG-9917 Phase I Dose-Escalating Study with an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC #673089) in Patients with Previously Untreated Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma (UCI)**
21. 0S-08-10 Epigenetics of Ovarian Cancer - Detection and Diagnosis (USC)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

22. **03092 Randomized Pilot Trial of Oral Cyclophosphamide vs. Oral Cyclophosphamide with Celecoxib for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (COH)**
23. 07007 Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer (COH)
24. **07187 Evaluation of Ovarian Cancer and Outcomes of Care (COH)**
25. 08032 A Standardized Nursing Intervention Protocol for Ovarian Cancer as a Chronic Illness (COH)
26. **AMG-479 As Second Line Therapy for Recurrent Platinum-Sensitive Ovarian Cancer (TRIO-015) (CS)**
27. AMG479 for First Line Treatment of Ovarian Cancer (TRIO14) (CS)
28. **GCD-0449 as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Remission (CS)**
29. Maintenance Chemotherapy Trial Comparing Paclitaxel or CT-2103 vs. No Treatment (CS)
30. **Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse (CS)**
31. Study to Compare the Safety and Efficacy of AZD2281 and Liposomal Doxorubicin in Patients With Advanced Ovarian Cancer (CS)
32. **Study to Test the Effectiveness of AZD2281 in Patients who Received at Least Two Platinum-Based Therapies (such as Carboplatin or Cisplatin) as Treatment Options for Their Ovarian Cancer (CS)**

B. Uterine /Cervical Cancer

1. GOG-0209 Phase III Randomized Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients With Stage III and Stage IV or Recurrent Endometrial Cancer (UCI)
2. **GOG-0213 Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab NSC #704865 (UCI)**
3. GOG-0249 Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High Risk, Early Stage Endometrial Carcinoma (UCI)
4. **GOG-0258 Phase III Randomized Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma (UCI)**
5. GOG-0076GG Phase II Limited Access Trial of Pemetrexed (Alimta, LY231514) (NSC#698037) in Combination with Cisplatin (NSC#119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix (UCI)
6. **07204 PHII-89; NCI #7713 Phase II Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma (COH)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244
www.CancerPACT.org

7. 08221 Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure (COH)
8. **06081 Cervical Cancer Survivorship among African American and Latina Survivors (COH)**

5. Head & Neck Cancer

1. **08236 RTOG 0619 Randomized Phase II Trial of Chemoradiotherapy vs. Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck (COH)**
2. UCI-08-36 Phase II Randomized Open-Label Study of IMC-A12, as a Single Agent or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Disease Progression on Prior Platinum-Based Chemotherapy (Appendix T) (UCI)
3. **UCI-98-34 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: Phase IIB Trial (BBIC) (UCI)**
4. **7H-08-2 Assessing the Role of Differentiated and Non-Differentiated Cell Types in the Development of Head and Neck Cancers (USC)**
5. 07121 Cetuximab at Either 500 or 750mg/m² Every Other Week for Platinum Refractory Cancer of the Head and Neck (COH)
6. **08138 City of Hope Head and Neck Database Using the American Head and Neck society Otobase (COH)**
7. GENMAB-GEN205 Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy (LLU)

6. Lung

1. **2N-06-7 Phase III Multi-Center Randomized Double-Blind Placebo-Controlled Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-III A Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors (USC)**
2. 2N-06-08 Phase III Multi-Center Randomized Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease (USC)
3. **09-02-056 Phase III Multicenter Randomized Open-Label Trial of Pemetrexed (ALIMTA) in Combination with Carboplatin and Bevacizumab Followed by Pemetrexed and Bevacizumab**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

vs. Paclitaxel, Carboplatin and Bevacizumab Followed by Bevacizumab as First Line Therapy in Stage IIIB/IV NSCLC (UCLA)

4. 1163 2N-05-4 Phase III Multicenter Placebo Controlled Double Blind Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (Erlotinib) Compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) after Failure of Standard First Line Chemotherapy (CTU)
5. **05124 ACOSOG Z4032 Phase III Randomized Study of Sublobar Resection Versus Sublobar Resection Plus Brachytherapy in High-Risk Patients with Non-Small Cell Lung Cancer (NSCLC), 3cm or Smaller (COH)**
6. 06068, OSI-OSI-774-302 OSI Radiant Phase III Multi-Center Randomized Double-Blind Placebo-Controlled Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR Positive Tumors (COH, CS, LLU)
7. **08126 Phase III Randomized Placebo-Controlled Study of Oral Talactoferrin in Combination with Carboplatin and Paclitaxel as First-Line Therapy in Patients with Locally Advanced or Metastatic Non-Small Lung Cancer (COH)**
8. 08141 Phase III Study of Pemetrexed, Cisplatin and Radiotherapy followed by Consolidation Pemetrexed vs. Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III NSCLC Other than Predominantly Squamous Cell Histology (COH)
9. **CALGB C140503 / HS 2008-0207 Phase III Randomized Trial of Lobectomy vs. Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer (UCI)**
10. ECOG E1505/ HS 2009-6772, CTSU/E1505 Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (4cm)-IIIA Non-Small Cell Lung Cancer (UCI, USC)
11. **NOVARTIS-CASA404A2301, UCI 07-72 / HS 2008-6373, 1281 Phase III Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)(ATTRACT 1) (CTU, LLU, UCI)**
12. PFIZER-A40206 Phase III Randomized Open Label Trial of CP-751,871 in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin in Patients with Non-Small Cell Lung Cancer (LLU)
13. **UCI 04-60 / HS 2005-4148 Phase III Randomized Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy (UCI)**
14. UCI 07-57 / HS 2008-6294, 07-11-063 Phase III Double-Blind Randomized Placebo-Controlled Study to Assess the Efficacy of recMAGE-A3 + AS15 Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients with Resectable MAG-A3-positive Non-Small Cell Lung Cancer (UCI, UCLA)
15. **UCI-08-66 Phase III Randomized Double-Blind Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) (Appendix T) (UCI)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771

City of Hope (COH) 877-482-4673

Loma Linda University Medical Center (LLU) 800-782-2623

UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839

UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719

USC Clinical Trials Unit (CTU) 323-442-9960

USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

16. UCI 08-01 / HS 2008-6267 Phase IIB/III Randomized, Double-Blind Trial of BIBW 2292 Plus Best Supportive Care (BSC) versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (UCI)
17. **2N-06-6 Phase II Study of the Halichondrin B Analog E7389 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane (USC)**
18. 2N-08-1 Phase II Randomized Double-Blind Placebo-Controlled Multi-Center Study of the Efficacy and Safety of Apricoxib in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients (USC)
19. **04-07-058 Phase II Randomized Open-Label Clinical Trial of Combination Erlotinib (Tarceva) and Fulvestrant (Faslodex) vs. Erlotinib (Tarceva) Alone in Advanced Non-Small Cell Lung Cancer Patients (UCLA)**
20. 08-05-021 Phase II Study to Assess the Safety and Efficacy of the Combination of Carboplatin, Paclitaxel and Bevacizumab +/- Combretastatin A4 Phosphate (CA4P) Followed by Bevacizumab +/- CA4P in Subjects with Chemotherapy Naive Stage IIIB/IV Non-Squamous Cell Histology Non-Small Cell Lung Cancer (NSCLC) (UCLA)
21. **06044 PHII-74 NCI #7437 Phase II Study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated with a Taxane (COH)**
22. 06094 PHII-65 NCI #7103, 18M-07-1 Phase II Study of AZD2171 (NSC #732208) in Patients with Malignant Mesothelioma (COH, USC)
23. **06254 Phase II Randomized Placebo-Controlled Clinical Trial of Combination Erlotinib (Tarceva) and Celecoxib (Celebrex) vs. Erlotinib (Tarceva)/Placebo in Advanced Non-Small Cell Lung Cancer Patients (COH)**
24. 07189 Phase II Open Label, Two Arm Trial to Evaluate the Efficacy of PF-00299804 in Patients with Advanced NSCLC After Failure of at Least One Prior Chemotherapy Regimen and Failure of Treatment with Erlotinib (COH)
25. **SWOG-S0720 Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC) (USC)**
26. UCI 06-62 / HS 2007-5833 Phase II Single-Arm Trial of BIBW 2992 in Non-Small Cell Lung Cancer Patients with EGFR Activating Mutations (UCI)
27. **UCI-08-49 Phase II Open Label Trial Of PF-00299804 In Untreated Advanced Adenocarcinoma Of The Lung In Never Or Former Light Smokers (UCI)**
28. 07-07-012 Phase I/II Study of Pemetrexed (Alimta) plus Carboplatin, or Pemetrexed plus Cisplatin with Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non-Small Cell Lung Cancer (UCLA)
29. **08105 Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients with Advanced Solid Tumors and in Chemotherapy-Naive Patients with Malignant Pleural Mesothelioma (COH)**
30. APTIUM-05LUN01 Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer (LLU)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

31. **1297 Phase IB/ II Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer (20060534) (2O-08-3) (CTU)**
32. 03-06-008 Phase I Trial of Intratumoral Administration of CCL21 Gene-Modified Autologous Dendritic Cells in Advanced Non-Small Cell Lung Cancer (UCLA)
33. **07152 Phase I Trial of External Beam Radiotherapy, Combined with Cisplatin and Etoposide OR Carboplatin and Paclitaxel, followed by Consolidation Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66), in Unresectable OR Medically Inoperable, Non-Metastatic CEA-Producing Stage III or IIB Non-Small Cell Lung Cancer (COH)**
34. 07243 Phase I Study of MM-10-001 In Advanced Non Small Lung Cancer (COH)
35. **2N-08-6 Development of DNA Methylation Markers for Early Detection of Lung Cancer (USC)**
36. 07-02-035 Pilot Study of Radiofrequency Ablation in High-Risk Patients with Stage 1A Non Small Cell Lung Cancer (UCLA)
37. **08-03-041 Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy (UCLA)**
38. 08-03-068 Monitoring Targeted Lung Cancer Treatments with FDG-PET/CT (UCLA)
39. **04114 The Relationship Between Coping, Gender and Psychological Adaptation in People with Lung Cancer (COH)**
40. 06002 SWOG S0424, HS 2005-4680 Molecular Epidemiology Case-Series Study of NSCLC in Smoking and Non-Smoking Women and Men (COH, UCI)
41. **08034 Palliative Care for Quality of Life and Symptom Concerns in Early Stage Lung Cancer (COH)**
42. 08035 Palliative Care for Quality of Life and Symptom Concerns in Late Stage Lung Cancer (COH)
43. **SANOFI-AVENTIS-EFC10261 Multinational Randomized Double-Blind Study Comparing Aflibercept vs. Placebo in Patients Treated with Second-Line Docetaxel after Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (LLU)**
44. SWOG S0533 / HS 2007-5576 Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab in 3 Cohorts of Patients with Inoperable Locally Advanced Stage III NSCLC (UCI, USC)
45. **SWOG S9925 / HS 2004-3518 Lung Cancer Specimen Repository Protocol (UCI, USC)**
46. A Study that Compares Overall Survival in High Risk Patients with Stage I Non-Small Cell Lung Cancer Receiving Either Lung Surgery Followed by Brachytherapy or Lung Surgery Alone (CS)
47. **Antigen-Specific Cancer Immunotherapeutic as Supplemental Therapy in Patients with Non-Small Cell Lung Cancer (CS)**
48. Collection of Data for the Society of Thoracic Surgeons (STS) Database for Patients that Will Undergo a Chest or Lung Procedure (CS)
49. **FDG-PET/CT as a Predictive Marker of Tumor Response and Patient Outcome: Prospective Validation in Non-Small Cell Lung Cancer (CS)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

50. Randomized Study to Test the Safety and Effectiveness of ASA404 / Placebo, in Combination with Docetaxel as a Second-Line Therapy for Metastatic, Non-Small Cell Lung Cancer (NSCLC) (CS)
- 51. Study of ASA404 in Combination with Paclitaxel and Carboplatin as Treatment for Non-Small Cell Lung Cancer (NSCLC) (CS)**
52. Study of the Cancer Vaccine Stimuvax in Non-Small Cell Lung Cancer Subjects with Unresectable Disease (CS)
- 53. Study to Evaluate Whether Selenium Yeast Tablet can Prevent New Lung Cancers in People with Surgically Removed Non-Small Cell Lung Cancer as Compared to Patients taking a Placebo Yeast (CS)**
54. Study to Test the Safety & Effectiveness of Pemetrexed + Cisplatin + Radiotherapy, Followed by Consolidation Pemetrexed vs. Etoposide + Cisplatin + Radiotherapy, Followed by a Chemotherapy of Choice, in Patients with Stage III Non-Small Cell Lung Cancer (CS)
- 55. Trial Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer (CS)**

7. Melanoma

- 1. SWOG-E1697 Phase III Randomized Study of Four Weeks High Dose IFN- \pm 2B in Stage T2B No, T3A-B, T4A-B No, and T1-4, N1A, 2A (Microscopic) Melanoma (LLU)**
2. SWOG_S0438 Phase II Randomized Trial of BAY 43-9006 (Sorafenib; NSC- 724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma (LLU)
- 3. UCI 02-23 / HS 2002-2763 Phase II Evaluation of Docetaxel and Vinorelbine Plus Sargramostim in Patients with Metastatic Malignant Melanoma (UCI)**
4. UCI06-06 Phase II Randomized Double Blind, Placebo-Controlled Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology (UCI)
- 5. 07-11-052 Phase I/II Study of Daily Oral Dosing with Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients with Metastatic and Unresectable Locally-Advanced Malignant Melanoma (UCLA)**
6. 08-07-063 Phase I/II Study of Daily Oral Dosing with Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients with Metastatic and Unresectable Locally-Advanced Malignant Melanoma (UCLA)
- 7. 02107 Identification of Genes and Pathways in Tumorigenesis and Progression of Malignant Melanoma (COH)**
8. UCI 06-08 / HS 2006-5033 Evaluation of Disulfiram Plus Arsenic Trioxide in Patients with Metastatic Melanoma and at Least One Prior Systemic Therapy (UCI)
- 9. UCI 07-66 / HS 2008-6099 Pilot Study to Evaluate the Correlation of Modified Two Layer Diffuse Optical Spectroscopy (MTLDOS) and SIAscopy as Compared to Clinical Examination and Histology of Pigmented Skin Lesions Based on Physiological Parameters (UCI)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

8. Prostate Cancer

1. **4P-09-6 Phase III Randomized Double-Blind Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Hormone (USC)**
2. 06135 SWOG S0421 Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer (COH)
3. **07215, CALGB 90203 Phase III Randomized Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer (COH, USC)**
4. 08043 RTOG 0534 Phase III Trial of Short Term Androgen Deprivation with Pelvis Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy (COH)
5. **RTOG-0534 Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA after Radical Prostatectomy (USC)**
6. SWOG-S0421 Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer (USC)
7. **4P-04-3 Phase II Study of PS-341 (Velcade, Bortezomib) and Docetaxel for Patients with Hormone-Refractory Prostate Cancer (USC)**
8. 4P-07-3 Phase II Trial of a Combination Herbal Therapy for Men with Biochemical Recurrence of Prostate Cancer After Initial Local Therapy (USC)
9. **06-11-097 Phase II Randomized Partially-Blinded Placebo-Controlled Study of Polyphenon E and Black Tea in Men Scheduled for Prostatectomy (UCLA)**
10. 1238 Phase II Randomized Double-Blind-Controlled Study with and without Enzastaurin in Combination with Docetaxel and Prednisone, Followed by Enzastaurin Maintenance as First-Line Treatment in Hormone Refractory Metastatic Prostate Cancer Patients (4P-06-5) (CTU)
11. **07013 Phase II Trial of Dasatinib (Sprycel) in Subjects with Hormone-Refractory Prostate Cancer, Previously Treated with Chemotherapy (COH)**
12. 08024 PHII-84, NCI#7659 Phase II Randomized Study of GW786034 (Pazopanib) in Stage DO Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy (COH)
13. **UCI 06-60 / HS 2007-5564 Phase II Trial of Dasatinib (Sprycel) in Subjects with Hormone-Refractory Prostate Cancer, Previously Treated with Chemotherapy (UCI)**
14. UCI 07-14 / HS 2007-5904 Phase II Pilot Study to Determine the Effects of Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate in Patients who are Scheduled for Radical Prostatectomy with Genomic Correlates of Pathological Response (UCI)
15. **UCI-BMS CA180-097 Phase II Trial of Dasatinib (Sprycel) in Subjects with Hormone-refractory Prostate Cancer, Previously Treated with Chemotherapy (LLU)**
16. 4P-06-3 Phase I/II Trial of Adjuvant 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0M0 Prostate Cancer (USC)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

17. **4P-09-2 Phase I/II Open-Label Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects (USC)**
18. 06-03-129 Phase I Open Label Single Center Multiple Dose Escalation Clinical Study of SU011248 in Subjects with High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy (UCLA)
19. **01-07-026 Comparison Study of a Low-Fat Diet Supplemented with Fish Oil and a Standard Western Diet in Individuals with Prostate Cancer (UCLA)**
20. 4P-01-2 Prostate Cancer Prostatectomy Data and Specimen Collection Project (USC)
21. **4P-05-1 FDG PET-CT in Metastatic Prostate Cancer (USC)**
22. 4P-06-4 Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial (USC)
23. **4P-08-4 Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study (USC)**
24. 4P-09-8 LHRH and LH Receptor Expression and Polymorphisms as Prognostic and Predictive Markers in Prostate Cancer (USC)
25. **05-07-059 Randomized Double-Blind Placebo-Controlled Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen Levels Following Surgery or Radiation for Prostate Cancer (UCLA)**
26. 07-11-002 Neoadjuvant Androgen Depletion in Combination with Vorinostat followed by Radical Prostatectomy for Localized Prostate Cancer: Total Androgen-Receptor Gene Expression Targeted Therapy (TARGET) (UCLA)
27. **07-12-021 Multicenter Randomized Double-Blind Study Comparing the Efficacy and Safety of Aflibercept vs. Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer (UCLA)**
28. 00149 Prostate Cancer Database (COH)
29. **04071 Erectile Dysfunction Recovery in Men age \leq 65 Treated with Bilateral Nerve Sparing Robotic Assisted Prostatectomy (BNS-RAP) for Prostate Cancer (COH)**
30. 05190 Androgen Deprivation and Localized Radiotherapy to Metastases in Patients with Oligometastatic Hormone - Sensitive Prostate Cancer (COH)
31. **07101 Long Term Follow Up after Prostate Cancer (COH)**
32. 07205 The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men with Prostate Cancer Age 65 and Older (COH)
33. **08239 Determination of the Reliability of Expressed Prostatic Secretion and Post Massage Urine Biomarkers in the Detection of Prostate Cancer in Men Undergoing Biopsy for Prostate Cancer (COH)**
34. CTSU/E3805 CHARTED: ChemoHormonal Therapy vs. Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (USC)
35. **MILLEN.-03-1218 VELCADE (Bortezomib) for Injection Therapy for Early Relapsed Prostate Cancer (LLU)**
36. Prostate Patients Profiles Project (P4) (CS)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

37. **Randomized Two-Arm Study to Test the Safety and Effectiveness of CP-751,871 in Patients with Advanced Prostate Cancer That Have Not Been Treated With Chemotherapy (CS)**
38. Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer (CS)
39. **Study to Examine Prostate Cancer Cells in the Blood of Patients with Prostate Cancer that has Spread Outside of the Prostate (CS)**

9. Urologic Cancers (other)

A. Bladder

1. **SWOG-S0337 Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer (USC)**
2. CTSU/CALGB90601 Phase III Randomized Double-Blinded Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (USC)
3. **4B-01-2 Randomized Comparison of the Studer Pouch vs. the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients (USC)**
4. 4B-02-2 Bladder Cancer Cystectomy Data and Specimen Collection Project (USC)
5. **1283, 4B-08-1 Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer (EFC6668) (CTU, USC)**
6. 05148 Bladder Cancer Database (COH)
7. **UCI04-35/ HS 2004-3920 Evaluation of Oxaliplatin and Gemcitabine in Patients with Metastatic Bladder Cancer (UCI)**

B. Kidney Cancer

1. **06090 CTSU/ECOG E2805, HS 2006-5386 Phase III Randomized, Double-Blind Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma (COH, UCI, USC)**
2. 4B-06-3 Phase II Randomized Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma (USC)
3. **08130, 4K-08-5 Phase II Randomized Open Label Multi-Center Study to Compare Bevacizumab Plus RAD001 vs. Interferon Alfa-2A Plus Bevacizumab for the First-Line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney (COH, USC)**
4. CTSU/E2804 The BeST Trial: Phase II Randomized Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma (USC)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

5. **4K-05-1 Phase I/II Trial of Bortezomib and Bevacizumab (“BB-mib-mab”) in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) with Assessment of Tissue Correlates of Response (USC)**
6. 1198 Phil-75, 4B-06-1 Phase I/II Study of E7389 Halichondrin B analog (NSC #707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency (CTU, USC)
7. **0I-05-2 Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies (USC)**
8. 4K-03-2 Kidney Cancer Data and Specimen Collection Project (USC)
9. **4K-08-6 Axitinib (AG-013736) as Second-Line Therapy for Metastatic Renal Cell Cancer: Axis Trial (USC)**
10. 07124, UCI 07-55 / HS 2007-6083 Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy (COH, UCI)
11. **07241 Development of a Blood Test of Anti-IMP3 Autoantibody for the Detection of Renal Cell Carcinoma with Metastasis and Metastatic Potential (COH)**
12. SWOG-E2805 Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma (LLU)
13. **UCI 08-39 / HS 2008-6632 A Study of Pazopanib vs. Sunitinib in Treatment of Subjects with Locally Advanced and /or Metastatic Renal Cell Carcinoma (UCI)**

10. Sarcoma

1. **07125 COG#ARST0531 Phase III Groupwise Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) vs. VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS) (COH)**
2. UCI-08-56 Phase III Double-Blind Randomized Trial of Pazopanib vs. Placebo in Patients with Soft Tissue Sarcoma Whose Disease has Progressed During or Following Prior Therapy (Appendix T) (UCI)
3. **07091 SARC-009 Phase II Trial of Dasantinib in Advanced Sarcoma (COH)**
4. 07181 SARC 011, N021157: SARC Global Collaboration Phase II Trial of R1507, A Recombinant Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients with Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas (COH)
5. **07216 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas (COH)**
6. **04090 Phase I/II Study of Nelfinavir in Liposarcoma (COH)**
7. 00019 COG D9902 A COG Soft Tissue Sarcoma Biology and Banking Protocol (COH)
8. **07132, UCI 08-28 / HS 2008-6488, 11S-07-1 Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bone Sarcomas (COH, UCI, USC)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

9. 07208 COG #AEWS0331 European Ewing Tumour Working Initiative of National Groups Ewing Tumor Studies 1999 (EURO-E-W.I.N.G. 99) (COH)

Hematologic Cancers

1. Leukemia

1. **06-05-079, 9L-06-1 Phase III Randomized Double-Blind Controlled Study Comparing Clofarabine and Cytarabine vs. Cytarabine Alone in Adult Patients 55 Years Old and Older with Acute Myelogenous Leukemia (AML) who Have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens (UCLA, USC)**
2. 07-10-083 Phase III Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (sAML) (UCLA)
3. **06208 COG #AAML0531 Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents and Young Adults (COH)**
4. COG-AALL0232 Phase III Study of High Risk B-Precursor Acute Lymphoblastic Leukemia (CS)
5. **09-02-097 Phase IIB Multicenter Randomized Open-Label Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection vs. Intensive Salvage Therapy in Adult Patients Less Than or Equal to 60 Years Old with AML in First Relapse Following an Initial CR Greater Than 1 Month Duration (UCLA)**
6. 07-07-087, 9L-07-1 Phase II Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (Vincristine Sulfate Liposomes Injection) in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-negative ALL Who Failed Two Treatment Lines of Anti-leukemia Chemotherapy (UCLA, USC)
7. **08-06-032 Phase II Single Arm Open-Label Study to Determine the Efficacy of 100 mg Twice Daily Oral Dosing of Midostaurin Administered to Patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease (UCLA)**
8. 08-09-066 Phase II Randomized Study of Oral Sapacitabine in Elderly Patients with Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndrome (UCLA)
9. **9L-06-4 Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (USC)**
10. 07174 Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients with Acute Leukemia (AL) (COH)
11. **05-11-032 Phase I/II Study of Revlimid in Combination with Azacitidine in Patients with Advanced Myelodysplastic Syndrome (MDS) (UCLA)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

12. 05021 Phase I-II Study of Escalating Doses of Large Field Image Guided Intensity Modulated Radiation Therapy (IMRT) using Helical Tomotherapy in Combination with Etoposide (VP-16) and Cytosan as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation for Patients with Poor Risk Acute Lymphocytic Leukemia (ALL) (COH)
13. **06007 Phase I/II Study of SKI-606 in Philadelphia Chromosome Positive Leukemias (Wyeth No. 3160A1-200-US) (COH)**
14. 07-06-028 Phase I Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects with Advanced Malignancies (UCLA)
15. **08-03-038 Phase I Study of LY573636-sodium in Patients with Relapsed or Refractory Acute Myeloid Leukemia (UCLA)**
16. 06212 PHI-57 NCI# 7689 Phase I Trial of GTI2040 in Relapsed, Refractory, or High Risk Leukemia and Myelodysplasia (COH)
17. **08047 BMS CA180157 Phase I Combination Study of Dasatinib Plus Vorinostat as Front Line Therapy in Accelerated Phase or Blast Crisis Chronic Myelogenous Leukemia (CML), and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) (COH)**
18. 07203 Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR (COH)
19. **UCI 04-04 / HS 2004-3801 Phase I Study of CCI-779 in Combination with Imatinib Mesylate in Chronic Myelogenous Leukemia (UCI)**
20. 04-09-054 High Risk B-Precursor Acute Lymphoblastic Leukemia (UCLA)
21. **06-10-076 Multi-Center Multi-National Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies following Myeloablative Therapy (UCLA)**
22. 07-11-107 Randomized Trial of Sirolimus-Based Graft versus Host Disease Prophylaxis after Hematopoietic Stem Cell Transplantation in Relapsed ALL (UCLA)
23. **08-05-081 Extension Study to the Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects with Hematologic Malignancies Following Myeloablative Therapy (UCLA)**
24. 9L-03-1 Treatment of Newly Diagnosed Adult Acute Lymphoblastic Leukemia with Intensified Post-Remission Therapy Containing PEG-Asparaginase (USC)
25. **00029 Long-Term Follow-Up Following Bone Marrow Transplantation: Core C of the Program Project Grant (P01 CA30206), Hematopoietic Cell Transplantation for Hematologic Malignancies (COH)**
26. 00182 Mechanisms of Response and Resistance to STI571 in CML (COH)
27. **01087 Immune Studies in Chronic Myelogenous Leukemia (CML) (COH)**
28. 02149 NMDP 2002-0063 Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries (COH)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244
www.CancerPACT.org

29. **03112 Pilot Study of High-Dose Chemotherapy with Busulfan, Melphalan, and Topotecan Followed by Autologous Hematopoietic Stem Cell Transplant in Advanced Stage and Recurrent Tumors (COH)**
30. 03162 Molecular Pathogenesis of Acute Leukemia and Myelodysplasia (COH)
31. **03185 COG AALL0232 High Risk B-Precursor Acute Lymphoblastic Leukemia (COH)**
32. 03186 COG AALL03B1 Classification of Acute Lymphoblastic Leukemia (COH)
33. **04133 Hematopoietic Cell Transplantation for Hematological Malignancies: Neuropsychological Function after Hematopoietic Cell Transplantation (COH)**
34. 04182 COG AALL02P2, 07-01-051 Treatment of Late Isolated Extramedullary Relapse from Acute Lymphoblastic Leukemia (ALL) (Initial CR1>18 Months) - A Group-Wide Pilot Study (COH, UCLA)
35. **05062 COG AALL0331 Standard Risk B-Precursor Acute Lymphoblastic Leukemia (COH)**
36. 06157 Influenza Specific Humoral and Cellular Immunity After Vaccination in Recipients of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation (COH)
37. **06163 A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin vs. Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission (COH, CS)**
38. 07036 Evaluation of Immune Responses Against Male-Specific Minor Histocompatibility Antigens (H-Y mHAg) in Recipients and Donors of Allogeneic Hematopoietic Stem Cell Transplantation (COH)
39. **07052 T2005-003 A Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia (COH)**
40. 07090 COG #AALL0434 Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (COH)
41. **07173 Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients with Multiple Myeloma Undergoing Hematopoietic Cell Transplantation (HCT) (COH)**
42. 07200 Evaluation of Clinical Utility of the Cylex and ImmunKnow Assay in Hematopoietic Cell Transplantation (COH)
43. **08009 HSCT-CHESS to Enhance Hematopoietic Transplant Recovery (COH)**
44. 09050 Immune Responses in Acute Leukemia and Chronic Myeloid Leukemia (COH)
45. **99088 SWOG S9910: Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary (COH)**
46. 92036 SWOG 9007 Cytogenetic Studies In Leukemia Patients (COH)
47. **NOVARTIS-CAMN107AUS09, 9L-07-1 Multi-Center Open-Label Exploratory Study of Bcr-Abl Kinetics in Adult Patients on Nilotinib with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) and a Suboptimal Molecular Response to Imatinib (LLU, USC)**
48. SWOG-S9910 Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary (USC)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

49. UCI 07-46 / HS 2007-6051 Assessment and Determination of Chemotherapy Resistance in Newly-Diagnosed or First Relapse Leukemia Patients (UCI)
50. Fibroblast growth factor and B-cell chronic lymphoid leukemia (CS)

2. Lymphoma

1. **06-05-095 Phase III Randomized Double-Blind Study of Oral Enzastaurin vs. Placebo as Maintenance Therapy Immediately Following First-Line Treatment for Patients with High-Risk Diffuse Large B-Cell Lymphoma (UCLA)**
2. 13NHL-06-4 Phase III Randomized Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma (USC)
3. **04044 COG AHOD0031 Phase III Group-Wide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents with Newly Diagnosed Intermediate Risk Hodgkin Disease (COH)**
4. 04-05-014 Phase II of Weekly Bortezomib Velcade in Patients with relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) (UCLA)
5. **06-10-095 Phase II Prospective Study of A High Dose, Short Course Regimen (R-CODOX-M/IVAC) Including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma (AMC 048) (UCLA)**
6. 05149 Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for B-Cell Non-Hodgkin Lymphoma Using Zevalin, Fludarabine and Melphalan (COH)
7. **06130 SWOG S0433 Phase II Study of Iodine-131 Labeled Monoclonal Antibody (I-131 Tositumomab) in Combination with Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B Cell NHL (COH)**
8. 06195 Phase II Study of Rituximab-ABVD in Classical Hodgkin's Lymphoma (COH)
9. **07076 Phase II Study of Yttrium-90-Labeled Anti-CD20 Monoclonal Antibody in Combination with High-Dose Beam (BCNU, Etoposide, Cytarabine and Melphalan) Followed by Autologous Stem Cell Transplantation for Patients with Poor Risk/Relapsed B-Cell Lymphoma (COH)**
10. 07195 Phase II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) Plus Rituximab in Indolent Non-Hodgkin's Lymphoma (COH)
11. **08088 Phase II Open-Label Single-Arm Study of RAD001 in Patients with Refractory Mantle Cell Lymphoma (COH)**
12. 09041 Phase II Trial of Non-Myeloblastic Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response (COH)
13. **AMC-048 Phase II Prospective Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt's and Atypical Burkitt's Lymphoma (USC)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

14. CELGENE-CC-5013-MCL-001 Phase II Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent, Lenalidomide (Revlimid) in Patients with Mantle Cell Non-Hodgkin's Lymphoma who have Relapsed or Progressed after Treatment with Bortezomib or are Refractory to Bortezomib (Protocol CC-5013-MCL-001) The "EMERGE" Trial (LLU)
15. **MILLEN.-C05012 Phase II Two-Arm, Non-Randomized, Multicenter Study of VELCADE (Bortezomib) Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Subjects with Relapsed Follicular Lymphoma (LLU)**
16. 1201, 13NHL-06-3 Phase I/IIA Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies (CTU, USC)
17. **04155 Phase I/II Study of VELCADE in Combination with Gemcitabine in Relapsed B-Cell Non-Hodgkin's Lymphoma (COH, USC)**
18. 08011 Phase IB Study to Evaluate the Safety and Tolerability of AMG 655 in Combination with Bortezomib or Vorinostat in Subjects with Relapsed or Refractory Lymphoma (COH)
19. **03131 Phase I Study of De-Immunized DI-Leu16-IL2 Immunocytokine in Patients with B-Cell Non-Hodgkin's Lymphoma (COH)**
20. 07109 PHI-58 NCI# 7943 Phase I Study of GX15-070 (NSC #729280) and Bortezomib in Aggressive Relapsed/Recurrent Non-Hodgkin's Lymphoma (COH)
21. **08099 Phase I Study Evaluating the Combination of the Deacetylase Inhibitor, LBH589 Plus the mTOR Inhibitor RAD001, in Relapsed and Refractory Adult Patients with Lymphoma (COH)**
22. 08227 Phase I Open Label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (COH)
23. **0S-03-2 Comprehensive Tissue Repository: A Study of the Biology, Pathogenesis, Etiology, and Genetics of B-Cell and T-Cell Lymphoproliferative Disorders (USC)**
24. 0S-07-3 DNA Methylation and Epigenetic Analysis of Archival Cancer Samples (USC)
25. **0S-08-6 Collection of Peripheral Blood for Testing Feasibility of Dendritic Cell Culture and Transfection in Patients with Hematologic Disorders (USC)**
26. 0S-08-7 An Exploratory Open-Label Non-Randomized Single Center Study of [F-18]HX4 (USC)
27. **0S-09-3 Prognostic Significance and Longitudinal Assessment of Patient-Reported Quality of Life and Symptoms in High-Risk Myelodysplastic Syndromes. A Large-Scale International, Observational Study (USC)**
28. 04-03-021 Pilot Study Inducing and Targeting EBV-TK in EBV-Positive Lymphomas by Combination of Bortezomib and Ganciclovir (UCLA)
29. **06-12-027 Single-Arm International Multi-Center Trial of HuMax-CD20, a Fully Human Monoclonal Anti-CD20 Antibody, in Patients with Follicular Lymphoma who are Refractory to Rituximab as Monotherapy or in Combination with Chemotherapy (UCLA)**
30. 13NHL-07-3 Rituximab Plus CHOP Given Every 15 days with Sargramostim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (USC)
31. **00043 Multicenter Evaluation of Non-Hodgkins Lymphoma patterns and Outcomes of Care Within the National Comprehensive Cancer Network (NCCN) (COH)**
32. 07035 Genetic Epidemiology of Non-Hodgkin's Lymphoma (NHL) (COH)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

33. **07131 Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Mantle Cell Lymphoma Patients in Remission for Use in T Cell Program (COH)**
34. 08193 A Pivotal Study of SGN-35 in Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) (COH)
35. **08219 Multicenter Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T- Cell Lymphoma (COH)**
36. 09071 Long-term Observational Follow-up Study of a Multicenter, Randomized, Double-blind, Placebo-controlled, Comparative Trial of AMD3100 (240ug/kg)plus G-CSF (10 ug/kg) Versus G-CSF (10 ug/kg) Plus Placebo to Mobilize and Collect $\geq 5 \times 10^6$ CD34+ Cells/kg in Non-Hodkin's Lymphoma Patients for Autologous Transplantation (COH)
37. **98117 Molecular Pathogenesis of Therapy-Related Leukemia (COH)**
38. 99067 High Dose Chemotherapy and Combination anti-HIV Therapy for HIV-Associated Hodgkin's and Non-Hodgkin's Lymphoma (COH)
39. **AMC-053 Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 Positive Relapsed/ Refractory AIDS-Associated Non-Hodgkin's Lymphoma (USC)**

3. Myeloma

1. **06143 Phase II Study of Maintenance Treatment with Sequential Bortezomib, Thalidomide and Dexamethasone Following Autologous Peripheral Blood Stem Cell Transplant in Patients with Multiple Myeloma (COH)**
2. 06169 PHII-73 NCI #7518 Phase II Study of VEGF Trap (NSC 724770) in Patients with MDS (COH)
3. **07019 CIBMRT 05-DCB Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy (COH)**
4. GLOUCESTER-CPI-08-0006 Phase II Trial of Romidepsin and Bortezomib for Multiple Myeloma Patients with Relapsed or Refractory Disease (LLU)
5. **ONCOTHERAPEUTIC-X05727/DOXIL Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone MMY2010 (DVD) for Patients with Newly Diagnosed Multiple Myeloma (MM) (LLU)**
6. 03-06-106 Phase I/II Trial of Autologous Peripheral Blood Progenitor Cell Transplantation with VELCADE Maintenance as Treatment for Intermediate-and Advanced Stage Multiple Myeloma (UCLA)
7. **16M-08-1 Phase I/II Multi-Center Open-Label Dose-Escalation Study of Elotuzumab (Humanized anti-CS1 Monoclonal IgG1 Antibody, Formerly HuLuc63) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies (USC)**
8. 1307 Phase I and II Multicenter Open-Label Dose Escalation Study of HULUC63 (Elotuzumab) and Bortezomib in Subjects with Multiple Myeloma Following One to Three Prior Therapies (CTU)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

9. **04064 Phase I/II Trial using Tandem High-Dose Therapy with Melphalan and Total Marrow Irradiation (TMI) with Peripheral Blood Progenitor Cell Support and Dexamethasone and Thalidomide Maintenance in Multiple Myeloma (COH)**
10. 05013 Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined with Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell Transplantation(HSCT) for Patients with Advanced Myeloid Malignancies (COH)
11. **Phase IB Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma (CS)**
12. 07-08-093 Phase 1 Study of CCI-779 in Combination with Dexamethasone in Multiple Myeloma (UCLA)
13. **08-02-005 Phase I Open Label Study of Noscapine HC1 (CB3304) in Patient with Relapsed or Refractory Multiple Myeloma (UCLA)**
14. 08-06-031 Phase 1 Safety Study of LY2127399 in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma (UCLA)
15. **1213 Phase I Multi-Center Open-Labe Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal IgG1 Antibody) in Subjects with Advanced Multiple Myeloma (CTU)**
16. 07005 Phase 1 Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma (COH)
17. **Phase I Study To Assess The Safety And Pharmacokinetics Of BB-10901 (huN901-DM1) Given As An Intravenous Infusion Weekly For Two Consecutive Weeks Every Three Weeks To Subjects With Relapsed And Relapsed/Refractory CD56-Positive Multiple Myeloma (CS)**
18. 09-01-061 An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma (UCLA)
19. **08046 CIBMTR: 07-REV Evaluation of Lenalidomide as Maintenance Therapy Post Allogeneic Hematopoietic Cell Transplantation for High Risk Multiple Myeloma (COH)**
20. Bone Marker Directed Dosing of ZOMETA (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma (CS)
21. **Long-term Follow-Up Study of AMD 3100 plus G-CSF vs. G-CSF plus Placebo in Multiple Myeloma Patients for Autologous Transplantation (CS)**
22. Research Study of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma to Compare the Side Effects and Effectiveness of Amifostine and High Dose Chemotherapy (Melphalan) (CS)
23. **Research Study to Determine The Efficacy and Safety of Rd in Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years of Age or Older or Not Candidates For Stem Cell Transplantation (CS)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

Phase I Studies

1. 09082 Phase IB Open label Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors (COH)
2. **0C-05-8 Phase I Study of IV Fenretinide in Patients with Malignant Solid Tumors (USC)**
3. 0C-06-3 Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors (USC)
4. **0C-07-3 Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination with Vandetanib (USC)**
5. 1116, 0C-04-3 PhI-42 Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies (CTU, USC)
6. 1167 0C-03-6 Phase I Trial of Daily 5-Aza' Deoxycytidine (DAC) and Sodium Phenylbutyrate in Patients with Solid Tumors (CTU)
7. **1172 0C-04-8 Phase I Study of VEGF-Antisense Oligonucleotide (VEGF-AS) Given as a Daily Fixed Dose Subcutaneous in the Treatment of Patients with Relapsed or Refractory Malignancies (CTU)**
8. 1196 PHI-54 Phase I Study of IV Fenretinide in Patients with Malignant Solid Tumors (OC-05-8) (CTU)
9. **1208 Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination with Vinorelbine in Advanced Solid Tumors (OC-05-6) (CTU)**
10. 1218 Phase I Study Evaluating the Combination of Lapatinib (GW572016) and Everolimus (RAD001) in Patients with Advanced Solid Tumors (SWOG-S0528) (CTU)
11. **1221 PHI-53, 0C-05-5 Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies (CTU, USC)**
12. 1229, 0C-99-1 Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine. (CTU, USC)
13. **1263, 0C-07-5 Phase I Dose Escalation Study of MK-8033 in Patients with Advanced Solid Tumors (CTU, USC)**
14. 1268 0C-07-9, PhI-60, 0C-07-9 Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction (NCI #8063) (CTU, USC)
15. **1302, SWOG-S0711 Phase I Pharmacokinetics Study of Dasatinib (BMS-354825) (NSC-732517: IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction (CTU, USC)**
16. 1306 PHI-62, 0C-08-4 Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas (CTU, USC)
17. **1313, 0C-09-3 Phase I Multi-Arm Dose Escalation Study of Brivanib Alaninate Combined with Several Chemotherapy Regimens in Subjects with Advanced or Metastatic Solid Tumors (CA 182030) (CTU, USC)**
18. 03109 Phase I Trial of PS-341 in Combination with Topotecan in Advanced Solid Tumor Malignancies (COH)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

19. 04151 PHI-50 NCI#6432 Phase I Pharmacokinetic Study of PS-341 in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group (COH)
20. **05122 Phase I Study of a Combination of High Selenium Brassica Juncea With Irinotecan and Capecitabine (COH)**
21. 05127 Phase I Safety and Pharmacokinetic Study of IT-101 in the Treatment of Advanced Solid Tumors (COH)
22. **05138 PHI-53 NCI#7251 Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies (COH)**
23. 06022 PHI-55 NCI#7427, 1219 Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors (COH, CTU)
24. **07106 Phase I Open-Label Dose Escalation First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics and Pharmacodynamics of GSK923295 in Subjects with Refractory Cancers (COH)**
25. 07238 PHI-60 NCI#8063 Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction (COH)
26. **07242 PHI-61 NCI#7967, 1262, 0C-07-7 Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies (COH, CTU, USC)**
27. **08129 Phase I Multi-Center Open Label Dosimetry Study of I-131-CLR1404 in Patients with Relapsed or Refractory Advanced Solid Tumors who have Failed Standard Therapy or for Whom No Standard Therapy Exists (COH)**
28. 08181 Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas (COH)
29. **UCI 07-40 / HS 2007-5963 Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (UCI)**
30. 1228, 0C-07-1 Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Malignancies and Normal Hepatic Function, and/or Hepatocellular Carcinoma with Impaired Hepatic Function (CTU, USC)
31. **1257 Multiple-Center Open-Label Dose Escalation Study of the Safety and Pharmacokinetics of Oral RNX 194204 Capsule Administered Daily for a Minimum of 4 weeks in Patients with Refractory Malignancies (0C-07-6) (CTU)**
32. 0C-07-1 Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma with Impaired Hepatic Function (USC)

Other

1. **1372 4A-09-01 Phase III Randomized Double-Blind Placebo-Controlled Study of OSI-906 in Patients with Locally Advanced or Metastatic Adrenocortical Carcinoma (CTU)**
2. 02079 COG ANBL0032 Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue (COH)

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

3. 04144 Phase III Randomized, Open-Label, Multicenter Study of High Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM and Autologous Transplantation with Auto CD34+ HPC vs. Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (COH)
4. **06110 BMT CTN 0402 Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate as Graft-vs.-Host-Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (COH)**
5. RTOG-0517 Phase III Randomized Trial to Evaluate RadioPharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer (USC)
6. **1258, 7H-07-1 Phase II/III Multi-center Open-Label Randomized Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in Comparison with Paclitaxel and Carboplatin against Anaplastic Thyroid Carcinoma (OXC4T4-302) (CTU, USC)**
7. UCI-08-71 Phase II/III Open Label Non-Randomized Multi-Center Study Of Positron Emission Tomography (PET) Imaging with [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation (UCI)
8. **4T-03-1 Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients with Refractory Germ Cell Carcinoma (USC)**
9. 06220 PHII-80 PHL-051 NCI #7502 Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas (COH)
10. **08165 Phase II Multi-Center Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA - Mismatched Bone Marrow for Patients with Hematologic Malignancies (COH)**
11. 09091 Phase II Open Label, Single Arm Study of Carfilzomib Maintenance Therapy in Subjects Previously Enrolled in Carilzomib Treatment Protocols (COH)
12. **SWOG-S0809 Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) (USC)**
13. 0S-00-15 Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer (USC)
14. **0S-00-16 Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer (USC)**
15. 0S-01-17 Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with Gemcitabine-Based Chemotherapy (USC)
16. **0S-01-18 Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with CPT-11-Based Chemotherapy (USC)**
17. 0S-04-5 Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients with Cancer (USC)
18. 0S-04-7 USC Tumor and Tissue Bank (USC)
19. **0S-08-9 Short-Term Starvation Prior to Standard Chemotherapy with Gemcitabine and Cisplatin: Feasibility and Impact on Toxicity (USC)**

Contact Organizations:

[Cedars-Sinai \(CS\) 800-233-2771](#)
[City of Hope \(COH\) 877-482-4673](#)
[Loma Linda University Medical Center \(LLU\) 800-782-2623](#)
[UC Irvine Chao Family Comprehensive Cancer Center \(UCI\) 877-827-8839](#)
[UCLA-Jonsson Comprehensive Cancer Center \(UCLA\) 888-798-0719](#)
[USC Clinical Trials Unit \(CTU\) 323-442-9960](#)
[USC Norris Cancer Center \(USC\) 323-865-0451](#)

Call (toll free) 1-888-729-0244

www.CancerPACT.org

20. 3C-06-1 Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination with Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-Containing Regimen Which Includes 5-FU (USC)
21. **08-03-041 Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy (UCLA)**
22. 00099 Innovative Underserved Community-Based Cancer Risk Screening (COH)
23. **99-03-047 Use of Erwinia L-asparaginase (NSC-06977) for Patients with Systemic Allergic Reaction to E. Coli L-Asparaginase or PEG-Asparaginase (UCLA)**
24. 1314, AMC 059 Phase I/II Trial of PTC-299 in Patients with HIV-Related Kaposi's Sarcoma (CTU, USC)
25. **1323 0C-09-4 Phase II Open-Label Trial of BIBW 2992 in Genetically Pre-Screened Cancers with EGFR and/or HER2 Gene Amplification or EFGR Activating Mutations (CTU)**
26. 3G-09-1 Phase IB Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas (USC)
27. **0181 Prospective Chart Review for Data Inclusion into Sentinel Node Working Group (COH)**
28. 1309 PhI-63, 0S-09-1 Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with Either BRCA 1/2-Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer (NCI#8282 UPCI#08-121) (CTU, USC)
29. **01094 COG ANBL00B1: Neuroblastoma Biology Studies (COH)**
30. 08076 Phase I Study of Escalating Doses of Radiation Therapy Using Helical Tomotherapy in Combination with Fludarabine (FLU) and Melphalan (MEL) as a Preparative Regimen for Allogeneic Hematopoietic Stem Cell (HSC) Transplantation in Patients with Advanced and Hematological Malignancies who Are Not Eligible for Fully Myeloblastic Regimen (COH)
31. **INV INT-HSUEH – AZACITIDINE Phase I Study of Azacitidine in combination with Cisplatin in Patients with Recurrent or Metastatic Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck (LLU)**
32. 02025 Long-Term Follow Up of Recipients of Gene Transfer Research at City of Hope (COH)
33. **03129 Obtaining Leukapheresed Peripheral Blood Mononuclear Cells from Healthy Volunteer Donors for Use in T Cell Program (COH)**
34. 04065 Effect of Differentiation Status and Tissue Specificity of Graft Cells on Graft-vs.-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation (COH)
35. **04085 Detection of Carcinomas Using 123Iodine-Labeled T84.66 Diabody Antibody Fragment to Carcinoembryonic Antigen (CEA) (COH)**
36. 04152 Acquisition of Peripheral Blood and Bone Marrow to Support Laboratory Correlative Studies (COH)
37. **04199 Allogeneic Stem Cell Transplantation with a Novel Conditioning Therapy Helical Tomotherapy, Melphalan, and Fludarabine in Hematological Malignancies (COH)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org

38. 05166 Monitoring Islet Graft Integrity with Bidirectional Pyrophosphorolysis- Activated Polymerization Allele-Specific Amplification (BI-PAP-A) Assays (COH)
39. **06072 Pre-Surgical EPS Biomarkers as Predictors of Recurrence (COH)**
40. 06129 Procurement and Research Evaluation of Human Blood and Tissues for Detection of Occult Malignancies Using the Polymerase Chain Reaction (PCR) (COH)
41. **06167 CTSU/ECOG, SWOG_TAILORX ECOG, 07-02-090 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial (COH, LLU, UCLA, USC)**
42. 06170 Determining the Utility of an Assessment Tool for Older Patients with Cancer (COH)
43. **06229 Acquisition of Peripheral Blood Stem Cells, Peripheral Blood and/or Bone Marrow Cells from Healthy Volunteers for Laboratory Studies (COH)**
44. 07142 The Effects of Cultural Health Beliefs, Health Behaviors, and Health Related Quality of Life on Cancer Survival Among Multiethnic Breast and Cervical Cancer Survivors (COH)
45. **07157 Age-Related Changes in Nanoparticle Albumin Bound (nab) Paclitaxel Pharmacokinetics and Pharmacodynamics (COH)**
46. 07202 Passport for Care: Implementation in Multiple Institutions (COH)
47. **07999 Evaluation of BCL-XL Specific Immunity (COH)**
48. 08029 Use of Pre-Operative Hypnosis to Reduce Post-Operative Pain and Anesthesia Related Side-Effects (COH)
49. **08065 COG ALTE05N1: Umbrella Long Term Follow Up Protocol (COH)**
50. 08072 SARC011-CBP/NO21157-CBP A Group Wide Biology and Banking Study for Phase II Studies of R1507 (COH)
51. **08101 COG ACCRN07 Protocol for the Enrollment on the Official COG Registry, the Childhood Cancer Research Network (CCRN) for Groupwide Participation (COH)**
52. 08131 Illness Perception, Pain and Symptom Distress in Gastrointestinal Cancers (COH)
53. **08147 Assessment of Older Adults with Cancer: Feasibility of Computer Survey Methodology (COH)**
54. 08242 Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life (COH)
55. **96144 Molecular Genetic Studies in Cancer Patients and Their Relatives (COH)**
56. 97000 COG 4941L: National Wilms Tumor Late Effects Study (COH)
57. **UCI 01-59 / HS 2002-2234 Development of a Diagnostic Assay for Kinase Activity in Malignant Cells (UCI)**
58. UCI 04-87 / HS 2004-3626 Measurement of Optical properties of Adult Human Muscle Tissue (UCI)
59. **UCI 07-03 / HS 2007-5510 Determining the Utility of an Assessment Tool for Older Patients with Cancer (UCI)**
60. UCI 07-22 / HS 2007-5868 Examination of PNH, by Level of CD59 on Red and White Blood Cells, in Bone Marrow Failure (UCI)
61. **UCI 98-20 / HS 1998-309 Investigation Into the Molecular Events Involved in the Development of Cancer (UCI)**

Contact Organizations:

Cedars-Sinai (CS) 800-233-2771
 City of Hope (COH) 877-482-4673
 Loma Linda University Medical Center (LLU) 800-782-2623
 UC Irvine Chao Family Comprehensive Cancer Center (UCI) 877-827-8839
 UCLA-Jonsson Comprehensive Cancer Center (UCLA) 888-798-0719
 USC Clinical Trials Unit (CTU) 323-442-9960
 USC Norris Cancer Center (USC) 323-865-0451

Call (toll free) 1-888-729-0244

www.CancerPACT.org